Who makes Cohort A: vilobelimab?

Cohort A: vilobelimab is developed by PPD Development, LP.

What development phase is Cohort A: vilobelimab in?

Cohort A: vilobelimab is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Cohort A: vilobelimab

PPD Development, LP · Phase 2 active Small molecule

At a glance

Generic name	Cohort A: vilobelimab
Sponsor	PPD Development, LP
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) (PHASE2)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab (PHASE2)
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cohort A: vilobelimab CI brief — competitive landscape report
Cohort A: vilobelimab updates RSS · CI watch RSS
PPD Development, LP portfolio CI